Latest news

• Lundbeck gets US approval for migraine drug at heart of Alder takeover

  It’s also the first and only intravenously-administered CGRP antibody, as the current three drugs – Amgen/Novartis’ Aimovig (erenumab), Teva’s Ajovy (fremanezumab) and Eli Lilly’s Emgality (galcanezumab) – are

• Lilly launches migraine med Reyvow at $640 per eight-pill pack

  Lilly’s other migraine med – CGRP antagonist Emgality (galcanezumab) – has begun to establish itself in the prevention category, but still lags behind first-in-class Aimovig (erenumab) from Novartis and

• Allergan gets FDA nod for first oral CGRP drug for migraine

  First to market among these the injectables was Amgen/Novartis’ Aimovig (erenumab), and it has since been joined by Eli Lilly’s Emgality (galcanezumab) and Teva’s Ajovy (fremanezumab), with intravenous

• Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

  Alder’s drug is given every three months, whereas Amgen’s  Aimovig(erenumab) and Lilly’s  Emgality(galcanezumab) are taken once a month and Teva’s  Ajovy(fremanezumab) is dosed either

• Eli Lilly scores positive phase 3 results for Emgality in treatment resistant migraine

  Hopes to catch up with rivals in the market. Eli Lilly has announced that its migraine prevention drug Emgality (galcanezumab) has produced positive results in its phase 3 study in patients ... activities. “There is a significant unmet need for